Benchling, which provides software for managing biotech research, raises $34.5M Series C led by Menlo Ventures
In a field where the laboratory notebook is still considered the state of the art, it's no wonder a company like Benchling, which provides software for managing life sciences research was able to nab $34.5 million.
Context & Ripple Effects
In mid-2019 Benchling was still a modest bet: a $34.5M Series C led by Menlo Ventures for software that replaces the paper lab notebook in [[entity/life-sciences-research|life sciences research]]. What followed validates the thesis — a $50M round at an $850M valuation within a year, then a $200M raise at $4B, then a $100M Series F at $6.1B barely two years after this round.
For Menlo Ventures, this deal sits at the start of an arc the firm itself has narrated since: it later raised $3B dedicated to backing AI-adjacent startups, its largest fundraising ever, while concentrating late-stage capital on Anthropic. The 2019 Benchling position is an early instance of the same pattern — infrastructure software for scientific work becoming venture-scale.
First-order effects
- Benchling gets capital to scale its research-data platform while the paper notebook remains standard practice in labs, letting it convert non-users before competitors establish a foothold.
- Menlo Ventures takes an early stake in a company whose valuation subsequently rose from sub-$200M implied levels to $6.1B across three follow-on rounds.
Second-order effects
- Adjacent players validate the same demand signal with their own rounds: BenchSci raises a $22M Series B and later a CA$95M Series D applying AI to drug-discovery workflows, while LatchBio raises a $28M Series A for biologist data tooling.
- Pharma and biotech buyers now face a fragmented but well-funded market of R&D software vendors competing on workflow integration rather than point tools.
Third-order effects
- If the funding cadence holds, biotech R&D consolidates around cloud platforms that own the data layer — the notebook becomes a legacy artifact and switching costs accrue to whoever holds experimental records.
- Investors who entered at the Series C stage, Menlo among them, gain the markups and credibility to redeploy into successive waves of scientific-computing and AI infrastructure bets.
The trend: Biotech R&D is shifting from paper notebooks to cloud data platforms, with each successive mega-round pulling more venture capital toward scientific-workflow software.